Effectiveness of Plasma Transfusions in Critical Care Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
INR > 1.2
Require FFP for active bleeding and/or prior to an invasive procedure
Are able to provide consent or proxy consent
Congenital or acquired coagulation factor deficiency
Platelet count < 50 x 109 /L and have NOT received subsequent platelet transfusion
Consumptive coagulopathy (bleeding ≥ 3 sites and ↓ plts, ↓ fib, ↑ d dimer)
Uncontrolled bleeding (6 or more units of blood in the last 6 hours)
Receiving therapeutic doses of heparin/heparinoid (must be off for at least 6 hours)
Have received clotting factor concentrates in the previous 24 hours
Are expected to require surgery in the next 48 hours
Survival expected to be less than 48 hours
Currently enrolled in another study with a similar outcome